---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-068845"
form_type: "8-K/A"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:40:18.239817+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Whitehawk closes sale of Aadi Subsidiary for $102.4M; pro forma cash $131M; FY2024 pro forma loss $25.2M

## Summary
- Sale closed March 25, 2025; total cash proceeds of $102.4M after purchase-price adjustments.
- Pro forma balance sheet as of Dec 31, 2024 shows cash & equivalents of $131.1M.
- Estimated gain on sale of $93.2M recorded; pro forma FY2024 net loss improves to $25.2M from historical $63.7M.
- Aadi revenue ($26.0M) and operating expenses ($64.3M) removed from pro forma statement.
- Stockholder approval obtained February 28, 2025; company retains no FYARRO program revenue.

## SEC filing metadata
- accession: 0001193125-25-068845
- form_type: 8-K/A
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312525068845/0001193125-25-068845-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312525068845/d924652d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-068845
- JSON: https://secwatch.observer/filing/0001193125-25-068845.json
- Plain text: https://secwatch.observer/filing/0001193125-25-068845.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.